Investor Relations

Press Releases

Webcast Image
Webcast
Q1 2021 Conformis, Inc. Earnings Conference Call
05/05/21 4:30 pm EDT
04/07/21
Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021
BILLERICA, Mass. , April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time .
03/16/21
Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay. BILLERICA, Mass. , March 16, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc.
03/03/21
Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results
BILLERICA, Mass. , March 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020 . Fourth Quarter 2020 Summary Total revenue of $16.7 million , a decrease of 16% year-over-year on a reported basis and 17%
03/01/21
Conformis, Inc. Announces Clearance in Australia for iTotal® PS, the Only Personalized, Posterior-Stabilized Total Knee Replacement System
The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient’s knee, and provide optimal stability throughout the full range of motion BILLERICA, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:
02/25/21
Conformis, Inc. to Participate in Upcoming Investor Conferences
BILLERICA, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate
02/12/21
Conformis, Inc. Announces Pricing of $85 Million Underwritten Offering of Common Stock
BILLERICA, Mass. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share. The gross proceeds from the offering will be approximately $85 million
02/11/21
Conformis, Inc. Announces Proposed Public Offering of Common Stock
BILLERICA, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis intends to grant the underwriters a 30-day option to purchase additional shares of its common stock
01/21/21
Conformis, Inc. and SITES Medical Announce Development & Supply Agreement
BILLERICA, Mass. and COLUMBIA CITY, Ind. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply
01/07/21
Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 3, 2021
BILLERICA, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2020 after the market closes on March 3, 2021 at approximately 4:00 p.m. Eastern Time .